SCHEMBL21456817

SCHEMBL21456817

CS(=O)(=O)NCC1CCCN(c2nc(N3CCOCC3)nc3ccccc23)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.57
▸ ALDH1A1 P00352 5/20 0.57
▸ GAA P10253 6/20 0.55
▸ GLA P06280 5/20 0.55
▸ HPGD P15428 3/20 0.55
▸ PIK3R1 P27986 3/20 0.54
▸ PIK3CA P42336 3/20 0.54
▸ PIK3CD O00329 2/20 0.54
▸ PIK3CB P42338 2/20 0.54
▸ KMT2A Q03164 1/20 0.49
▸ HSD17B10 Q99714 3/20 0.48
▸ TSHR P16473 3/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ PRKDC P78527 3/20 0.45
▸ MTOR P42345 1/20 0.44
▸ PDE5A O76074 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26551931 0.85 KDM4E (0.59) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL21456821 0.83 NPY5R (0.45) ALDH1A1PIK3R1PIK3CAPIK3CDPIK3CB
SCHEMBL21664313 0.82 GBA1 (0.57) KMT2AHSD17B10TSHRLMNACYP1A2
SCHEMBL21456834 0.82 NPY5R (0.44) KDM4EALDH1A1PIK3R1PIK3CAPIK3CD
SCHEMBL21456820 0.81 NPY5R (0.48) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL21664309 0.80 LMNA (0.50) LMNAPRKDCADRA2ANPY5R
SCHEMBL21664311 0.79 TSHR (0.58) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL21664418 0.78 PRKDC (0.69) PRKDC
SCHEMBL30562952 0.76 PRKDC (0.58) LMNACYP1A2CYP3A4PRKDC
SCHEMBL21664260 0.76 PRKDC (0.58) LMNACYP1A2CYP3A4PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551188-B1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RES INST (US) 2023-10-18 — — EP disclosed
EP-3551188-B1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RES INST (US) 2023-10-18 — — EP disclosed
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2023-09-12 — — US disclosed
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2023-09-12 — — US disclosed
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2023-06-08 — — US disclosed
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2023-06-08 — — US disclosed
US-11524010-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors SOUTHERN RESEARCH INSTITUTE (US) 2022-12-13 — — US disclosed
US-20210369713-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS SOUTHERN RESEARCH INSTITUTE (US) 2021-12-02 — — US disclosed
US-20200038402-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-02-06 — — US disclosed
EP-3551188-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS Southern Research Institute (US) 2019-10-16 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200038402-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXN2, TXNRD1 KDM4E 4229/4885ALDH1A1 3669/4885GAA 2131/4885
US-11524010-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 KDM4E 3849/4885ALDH1A1 3980/4885GAA 1942/4885
US-20210369713-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXNL1, TXN2 KDM4E 3849/4885ALDH1A1 3980/4885GAA 1942/4885
US-20230172932-A1 SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS TXN, TXNL1, TXN2 KDM4E 3849/4885ALDH1A1 3980/4885GAA 1942/4885
US-11752153-B2 Substituted quinazoline sulfonamides as thioredoxin interacting protein (TXNIP) inhibitors TXN, TXNL1, TXN2 KDM4E 3849/4885ALDH1A1 3980/4885GAA 1942/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback